98. Eosinophilic gastrointestinal disease Clinical trials / Disease details
Clinical trials : 172 / Drugs : 149 - (DrugBank : 39) / Drug target genes : 38 - Drug target pathways : 135
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04835168 (ClinicalTrials.gov) | January 30, 2022 | 10/3/2021 | Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis | A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: BT-11 500mg;Drug: BT-11 1000mg;Drug: BT-11 Placebo | Landos Biopharma Inc. | NULL | Not yet recruiting | 18 Years | 65 Years | All | 36 | Phase 1 | NULL |